ReviewDEN open2025
Endoscopic risk factors to inform early detection of gastric cancer after
Review in DEN open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between map-like redness and the risk of gastric cancer and high-risk precancerous lesions: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Gastric Cancer after <italic>Helicobacter pylori</italic> Eradication: Characteristics, Diagnosis, and Management.Digestion · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Methods: Medline and PubMed were searched for randomized controlled trials, cohort studies, and case-control studies published in the English-language medical literature between January 1997 and July 2023. The included articles assessed the correlation between post-eradication GC and pre- and post-eradication endoscopic findings, and associated post-eradication GC with gastric atrophy, intestinal metaplasia (IM), map-like redness, and xanthoma. Results: A total of 963 articles were retrieved. In these articles, 66 papers were finally included, comprising randomized controlled trials, cohort studies, and case-control studies. The included articles addressed gastric atrophy (16 studies), IM (eight studies), map-like redness (six studies), and xanthoma (two studies). Risk ratio (RR) of incident post-eradication GC was 3.40 (95%confidence interval [95%CI]: 1.98-5.84; Conclusions: Endoscopic atrophy, IM, and xanthoma observed at pre- and post-eradication time points and post-eradication map-like redness were suggested as endoscopic risk factors for post-eradication GC. Further studies are needed to clarify the risk of post-eradication GC based on these risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.